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 Androgen-deprivation therapy (ADT) is the standard of care for treatment of non-
resectable prostate cancer (PCa). Despite high treatment efficiency, most patients ultimately 
develop lethal castration-resistant prostate cancer (CRPC). In this study, we performed a 
comparative proteomic analysis of three in vivo, androgen receptor (AR)–responsive orthograft 
models of matched hormone-naive PCa and CRPC. Differential proteomic analysis revealed 
that distinct molecular mechanisms, including amino acid (AA) and fatty acid (FA) 
metabolism, are involved in the response to ADT in the different models. Despite this 
heterogeneity, Schlafen family member 5 (SLFN5) was identified as an AR-regulated protein 
in CRPC. SLFN5 expression was high in CRPC tumors and correlated with poor patient 
outcome. In vivo, SLFN5 depletion strongly impaired tumor growth in castrated conditions. 
Mechanistically, SLFN5 interacted with ATF4 and regulated the expression of LAT1, an 
essential AA transporter. Consequently, SLFN5 depletion in CRPC cells decreased intracellular 
levels of essential AA and impaired mTORC1 signalling in a LAT1-dependent manner. These 
results confirm that these orthograft models recapitulate the high degree of heterogeneity 
observed in CRPC patients and further highlight SLFN5 as a clinically relevant target for 
CRPC. 
 
Significance: This study identifies SLFN5 as a novel regulator of the LAT1 amino acid 
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 Androgen deprivation therapy (ADT), together with direct targeting of the androgen 
receptor (AR) pathway, remains the most effective treatment for patients with advanced 
prostate cancer (PCa). However, patients that relapse will ultimately develop a lethal form of 
the disease, termed castration-resistant prostate cancer (CRPC), with current second line 
therapeutic options providing only relatively short gain in survival. Therefore, a better 
understanding of the molecular mechanisms underlying treatment resistance and the 
identification of specific CRPC markers remain a subject of intensive research focus.  
 Targeting cancer metabolism, using small molecule inhibitors or diet manipulation, 
alone or in combination with existing drugs, represents an appealing option to further refine 
anti-cancer therapies (1). Due to the basal metabolism of the prostate gland, PCa is associated 
with distinct metabolic features, such as a reliance on oxidative phosphorylation (2) in the early 
stage of the disease. Progression to CRPC, as well as resistance to treatment, is often 
accompanied with a metabolic switch that renders PCa tumours increasingly dependent on 
specific metabolic pathways such as glycolysis (3), lipid and cholesterol metabolism (4). 
Alteration of cancer cell metabolism can result from the activation of multiple signalling 
pathways, which are often strongly inter-connected between each other. In prostate, AR has 
been shown to directly control glucose and lipid metabolism of cancer cells, thus supporting 
cancer progression (5) or treatment resistance (6). In addition to AR, mTORC1 signalling is 
frequently dysregulated in PCa (7). Regulation of cellular metabolism and protein synthesis by 
mTORC1 is critical to sustain the biomass required for enhanced proliferation in cancer cells. 
However, the limited success achieved by current mTOR inhibitors in clinics points towards 
the need to better characterise other factors upstream of mTOR regulation (8).  
 Along with growth factors, amino acid (AA) homeostasis is essential for the regulation 
of mTORC1 activity. Leucine, in particular, is critical for mTORC1 localisation at the surface 
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of lysosomes (9). Thus, an important component of this metabolic process is the L-type amino 
acid transporter LAT1. Mechanistically, LAT1 mediates the intracellular uptake of branched 
chain and aromatic AA in exchange for glutamine, in a sodium-independent manner (10). 
LAT1 over-expression has been reported in multiple cancer types, including PCa (11). In 
patients, LAT1 expression is elevated following ADT and in metastatic lesions (12,13). 
Mechanistically, LAT1 is regulated by the stress-induced transcription factor ATF4 and 
contributes to PCa progression, at least in part, by sustaining mTORC1 signalling (13). 
 Schlafen family member 5 (SLFN5) is a member of the Schlafen family of proteins, a 
group of type 1 interferon-inducible proteins. In addition to an AAA (ATPase) domain and a 
specific SLFN box, the SLFN5 gene contains a helicase domain as well as a nuclear localisation 
sequence, which suggests a role for this protein in transcription-related processes (14). 
However, the molecular function of SLFN5, as well as its contribution to cancer, remains 
unclear. SLFN5 levels correlate with good patient outcome in melanoma (15), breast (16) and 
renal cancers (17), and SLFN5 expression was associated with decreased cell motility in these 
cell types. A recent study further reported that SLFN5 negatively regulates invasiveness and 
epithelial-to-mesenchymal transition in breast cancer cells by directly controlling the 
transcription of ZEB1 (18). By contrast, a pro-tumourigenic role for SLFN5 has been suggested 
in glioblastoma, where SLFN5 acts as a transcriptional co-repressor of STAT1 following type 
1-interferon treatment (19). Taken together, these results suggest that the role of SLFN5 in 
cancer progression might be context-dependent.  
 In this study, we develop and characterise three in vivo, AR-driven, orthograft models 
of PCa that accurately model patient CRPC condition. In depth proteomic analysis reveals a 
complex response to hormone deprivation therapy, indicating distinct molecular mechanisms 
across the different models. Despite this molecular heterogeneity, we identify SLFN5 as a 
common target, the expression of which is consistently up-regulated upon ADT resistance. 
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SLFN5 expression is increased in treatment-resistant patient biopsies, while SLFN5 deletion 
dramatically impairs the growth of CRPC tumours in vivo. Mechanistically, we show that 
SLFN5 directly interacts with ATF4 and strongly controls the expression of several ATF4-
enriched target genes, including the AA transporter LAT1. Consequently, we demonstrate that 
SLFN5 knockout (KO) in CRPC cells alters AA metabolism and disrupts mTORC1 signalling 
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Materials and Methods 
Cell culture 
 Hormone naïve cells (CWR22res, LNCaP and VCaP) were cultured in RPMI medium 
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% foetal bovine 
serum (FBS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 2 mM glutamine 
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA). Castration-resistant cells (22rv1 and 
LNCaP AI) were cultured in androgen-deprived medium consisting of phenol-free RPMI 
(Gibco, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% charcoal 
stripped serum (CSS, Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and 2 mM 
glutamine. All cells were kept in incubators set at 37°C and 5% CO2. LNCaP (ATCC CRL-
1740), 22Rv1 (ATCC CRL-2505), and VCAP (ATCC CRL-2876) were obtained from ATCC. 
CWR22Res cells (hormone-responsive variant of CWR22 cells) were obtained from Case 
Western Reserve University, Cleveland, Ohio. LNCaP AI and CWR22Rv1-AR-EK cells were 
obtained from Newcastle University, UK. All cell lines were authenticated by STR DNA 
profiling and were routinely tested for mycoplasma (every ~6 weeks) using the Mycoalert 
mycoplasma detection kit (Lonza, Basel, Switzerland). Cells were kept in culture for a 
maximum of 10 passages after recovery from frozen vials. 
 
Generation of stable knockout and overexpressing cells 
 All plasmids were transfected into 106 cells using Cell Line Nucleofector Kit V (Lonza, 
Basel, Switzerland) and the T-013 program of a Nucleofector 2b Device (Lonza, Basel, 
Switzerland). 
 22rv1 and LNCaP AI cells were transfected with commercially available SLFN5 
CRISPR/Cas9 KO Plasmid (sc-408333) and SLFN5 HDR Plasmid (sc-408333-HDR) or 
control plasmids (Santa Cruz Technologies, Dallas, TX, USA). Cells were then put under 
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clonal selection to generate single-cell colonies. CTL and KO clones were then expanded and 
further selected for experiments based on SLFN5 protein expression. 
 For overexpressing cells, LNCaP cells were transfected with SLFN5 (NM_144975) 
Human MYC-Tagged ORF Clone (RC216330, Origene, Rockville, MD, USA) or the 
corresponding empty vector plasmid (PS100001, Origene, Rockville, MD, USA). 22Rv1 
SLFN5 KO cells were further transfected with SLC7A5 (NM_003486) Human Tagged ORF 
Clone (RC207604, Origene, Rockville, MD, USA). Cells were then clonally selected, 




 750.000 cells were seeded in 6-well plates and allowed to attach overnight. The next 
day, transfections were performed using Lipofectamine RNAimax (Invitrogen, Thermo Fisher 
Scientific, Waltham, MA, USA) according to the manufacturer’s protocol. ON-TARGETplus 
smartpool siRNAs against AR (L-003400-00) and ATF4 (L-005125-00), as well as non-
targeting siRNA (D-001810-01-20) were purchased from Dharmacon (Dharmacon, Horizon 
inspired cell solutions, Cambridge, UK). AR-Vs targeting siRNA (sequence 
CAAGGGAGGUUACACCAAA) was a kind gift from Newcastle University. RNA or protein 
extraction was performed 72 hours after transfection.  
 
Cell migration 
 LNCaP AI and 22rv1 cells were kept in serum-free medium for 24 hours before the 
experiment. Next, 500 µl of FBS-supplemented medium were dispensed in a 24-well plate. 
Cells were then trypsinised and resuspended in serum-free medium at a concentration of 106 
cells/ml (LNCaP AI) and 5×105 cells/ml (22rv1), and 500 µl of the cell suspension was added 
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on top of 8 µm pores inserts (Corning, New York, MA, USA). After 48 hours, the inserts were 
fixed in 100% methanol for 30 minutes at -20°C and subsequently stained with hematoxylin 
for 30 minutes at room temperature. Insert membranes were then washed with tap water and 
cells on the upper side were scrapped with a wet cotton bud. Finally, membranes were cut from 
the insert and mounted onto microscopy slides. Images were taken with a Zeiss AXIO 
microscope (Zeiss, Oberkochen, Germany) and further quantified using ImageJ software (v. 
1.46r) or by manual counting.  
 
Human CRPC orhografts 
 In vivo experiments were performed in accordance with the ARRIVE guidelines (20), 
and were reviewed by a local ethics committee under the Project Licence P5EE22AEE in full 
compliance with the UK Home Office regulations (UK Animals (Scientific Procedures) Act 
1986). Prostate cancer cells were suspended in serum-free RPMI medium and mixed 1:1 with 
Matrigel (Corning, NY, USA). Briefly, 14×106 cells (in 50 μl) were injected into the anterior 
prostate of CD1-nude mice (Charles River Laboratories, Wilmington, MA, USA). For CRPC 
conditions, orchidectomy was performed at the time of injection. Tumour growth was 
monitored weekly using A Vevo3100 ultrasound imaging system (Fujifilm Visualsonics, The 
Netherlands). Tumours were then allowed to grow for 9 weeks before reaching endpoint. At 
the end of the experiment, tumour orthografts were collected and weighted. Half of the tumour 
material was fixed in 10% formalin for histological procedures and the other half was snap-
frozen in liquid nitrogen for protein, mRNA, and metabolite extractions. 
 
Proteomic analysis of paired HN and CRPC orthografts 
 A detailed procedure of the proteomic analysis is given in Supplementary Methods. 
Briefly, 2-5 mg of tumour powder were resuspended in 150 µl of 4% SDS containing protease 
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and phosphatase inhibitors. Samples were then sonicated and centrifuged at 16000 × g for 10 
minutes. Supernatant was collected and quantified using the BCA protein assay kit (Thermo 
Fisher Scientific, Waltham, MA, USA). Following protease digestion, peptides were 
fractionated using high pH reverse phase chromatography and further separated and analysed 
on an EASY-nLC II (Thermo Fisher Scientific, Waltham, MA, USA) coupled to a Linear Trap 
Quadrupole Orbitrap Velos mass spectrometer (Thermo Fisher Scientific, Waltham, MA, 
USA). MS data were processed with MaxQuant v. 1.5.2.8 and resulting proteingroups.txt 
output files were analysed in Perseus v. 1.5.2.4. 
 
Transcriptomic analysis 
 A detailed procedure of the transcriptomic analysis is given in Supplementary Methods. 
Briefly, frozen tumours were manually crushed, reduced into powder and further processed 
using QIAshredder homogeniser columns (Qiagen, Hilden, Germany) before extraction. For 
cells, RNA was extracted 72 hours after initial seeding, when cells reached around 80% 
confluence. RNA extraction was performed using RNeasy Mini Kit (Qiagen, Hilden, Germany) 
with on-column DNase digestion (RNase-Free DNase Set, Qiagen, Hilden, Germany). Quality 
of the purified RNA was tested on an Agilent 2200 Tapestation using RNA screentape.  
 Libraries were prepared using Illumina TruSeq Stranded mRNA LT Kit (Illumina, San 
Diego, CA, USA) and run on the Illumina Next Seq 500 using the High Output 75 cycles kit 
(2 x 36 cycles, paired end reads, single index; Illumina, San Diego, CA, USA). FastQ files 
were generated using Illumina’s bcl2fastq (v. 2.20.0.422). RNA-Seq paired-end reads were 
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 For a detailed procedure of the metabolomic analysis, please refer to Supplementary 
Methods. 106 cells were seeded in 6-well plates. The next day, medium was replaced and cells 
were allowed to grow for 48 hours. Cells were then washed 3 times with ice-cold PBS and 
metabolites were extracted by adding 1 ml of ice-cold extraction buffer (50% Methanol, 30% 
acetonitrile, 20% H2O). Plates were incubated on a shaker at 4°C for 5 minutes and supernatant 
was collected, centrifuged at 16,000 × g for 10 minutes and finally transferred to HPLC glass 
vials. Samples were kept at -80°C prior to LC-MS analysis.  
 MS data were acquired using a Q Exactive Orbitrap mass spectrometer (Thermo 
Scientific, Waltham, MA, USA) coupled with a Thermo Ultimate 3000 HPLC system 
according to (21). Data analysis was performed using Thermo TraceFinder v. 4.0 software. 
 
Immunohistochemistry and analysis 
 All patients involved in this study gave their written informed consent. These studies 
were conducted in accordance with recognised ethical guidelines UBC CREB number: H09-
01628 and the amendment has been reviewed by the Chair of the University of British 
Columbia Clinical Research Ethics Board and the accompanying documentation was found to 
be acceptable on ethical grounds for research involving human subjects. Biochemical relapse 
was defined according to the ASTRO definition and represents three consecutive rise of 
detectable PSA following surgery. 
 To assess SLFN5 protein levels, immunohistochemistry was conducted with the 
Ventana DISCOVERY Ultra (Ventana Medical Systems, Tucson, Arizona, USA), an 
automated staining platform. Formalin-fixed paraffin-embedded (FFPE) TMA sections were 
baked, deparaffinised, and incubated in antigen retrieval solution CC1 (Ventana) at 95oC for 
64 minutes. Following, anti-SLFN5 antibody (rabbit, 1:100, ab121537, abcam,) was incubated 
at room temperature for 1 hour. For detection, UltraMap DAB anti-Rb Detection Kit (Ventana) 
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was used. Stained slides were scanned with Leica Aperio AT2 (Leica Microsystems, Concord, 
Ontario, Canada). The area of interest in the tumour images were delineated by pathologist. 
Positively stained cells were quantified with Aperio ImageScope (Leica Biosystems, Buffalo 
Grove, Illinois, USA).  
 
Analysis of SLFN5 binding motifs 
 Analysis of putative SLFN5-binding motifs (18) in the promoter regions of SLC7A5, 
SLC3A2, ATF4, NDNF and STRBP was done with the Motif-based sequence analysis tools 
FIMO package (22) (MEME Suite v. 5.1.1). Promoter regions were defined as 2000bp 
upstream of the transcription start site using the ensemble GRCh38.93 genome assembly.   
 
Statistical analysis 
 Statistical analyses were performed using GraphPad PRISM software v. 8.4.2 
(GraphPad Software Inc, San Diego, CA, USA). 
 
Antibodies and primers 
A list of the antibodies used in this study is provided as Supplementary data 6. The primers 
used in this study are listed in Supplementary Data 7. 
 
Data reproducibility 
Figure 1: Panel D: representative image from 3 independent biological experiments. 
Figure 2: Panel A: n = 1 gel loaded with three tumour orthografts per condition. Panel B: 
representative image from 3 tumour orthografts per condition. Panels C, F, G: representative 
image from 3 independent biological experiments. Panel D, H: n = 6 (3 independent biological 
experiments performed in duplicates). Panels E, I, K: n = 3 independent biological experiments. 
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Figure 3: Panels A, B: n = 151; 162; 45; 29 for untreated; NHT-treated; CRPC and NEPC 
respectively. Panel C: n = 38 for high SLFN5 expression and n = 47 for low SLFN5 expression. 
Panel D: n = 70 for Gleason score < 7 and n = 56 for Gleason score >7. Panel E: n = 153 for 
non-metastatic patients and n = 75 for metastatic patients. 
Figure 4: Panels A, B, C, D, E: representative experiment chosen from 3 independent biological 
experiments. Panel C, D, E: n = 6 (3 independent fields taken from two independent migration 
inserts per condition). Panels F, G: representative image from 8, 9, 7 tumours for CTL, KO1 
and KO2 respectively. Panels H, I: n = 8, 9, 7 tumours for CTL, KO1 and KO2 respectively. 
Figure 5: Panel A: representative image from 3 independent biological experiments. Panel D: 
n = 6 (3 independent biological experiments performed in duplicates). 
Figure 6: Panels A, B, C, D, E: representative image from 3 independent biological 
experiments. Panel F: n = 6 (3 independent biological experiments performed in duplicates). 
Panel H: representative image from 2 independent biological experiments. Panel I: 
representative image from 3 independent biological experiments. 
Figure 7: Panel A: n = 3 independent biological experiments. Panels B, C: representative image 
from 3 independent biological experiments. Panel D: n = 1 gel loaded with four tumour 
orthografts per condition. 
 
Data availability 
 The raw files and the MaxQuant search results files have been deposited as partial 
submission to the ProteomeXchange Consortium via the PRIDE partner repository (23) with 
the dataset identifiers PXD021405 and PXD021428. The following databases were used in this 
study: The Cancer Genome Atlas (TCGA—https://tcga-data.nci.nih.gov/tcga/); GEPIA 
(http://gepia.cancer-pku.cn/); STRING v11.0 (https://string-db.org/cgi/input.pl). All the data 
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supporting the findings of this study are available within the article and its supplementary 
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Proteomic characterisation of in vivo models of CRPC 
 To study resistance to androgen deprivation, we developed three independent PCa 
orthograft models to mimic clinical CRPC by injecting matched pairs (hormone naïve and 
castration resistant) of AR-proficient human PCa cell lines into the prostate of immuno-
deficient mice. In CRPC conditions, orthotopic injection was directly followed by 
orchidectomy to achieve ADT. LNCaP, CWR22res and VCaP were selected based on their 
differences in AR expression, full length and variants, and herein referred to as hormone naïve 
cells (HN) (Supplementary Figure 1a). HN cells were cultured in vitro in androgen-containing 
medium (supplemented with foetal bovine serum) and injected orthotopically into the prostate 
of uncastrated mice. By contrast, two matched, isogenic, androgen-independent (CRPC) cell 
lines, namely LNCaP AI and 22rv1, were routinely cultured in vitro in androgen-deficient 
medium (supplemented with charcoal-stripped serum) and orthotopically injected into 
castrated mice. VCaP cells, which were able to grow orthotopically in castrated mice, were 
injected into both uncastrated and castrated mice (Figure 1a). All models develop CRPC 
tumours in vivo and have been individually used in the literature (24). Surprisingly, the castrate 
models of LNCaP AI and VCaP-CR orthografts displayed a higher incidence than their HN 
counterparts. By contrast, CWR22res were more tumourigenic than 22rv1 (Supplementary 
Figure 1b). Importantly, there was no significant difference in the final tumour weight between 
HN and CRPC models (Supplementary Figure 1c). 
Using a SILAC-based proteomic approach, we compared the proteomes of the CRPC 
and HN tumours within each model. This allowed us to define three independent proteomic 
signatures associated with CRPC (Figure 1b, Supplementary Data 1). Strikingly, enrichment 
pathway analysis highlighted changes in metabolism as the top pathway commonly modulated 
in CRPC (Figure 1c). In particular, pathways related to lipid (PPAR signalling, fatty acid 
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oxidation, ferroptosis) and amino acid metabolism (branched chain AA degradation) were 
significantly modulated upon ADT resistance (Figure 1c). However, the regulated proteins 
involved in these pathways varied greatly among the models, emphasising the molecular 
heterogeneity of CRPC (Supplementary Data 1). For instance, the 22rv1 model was 
characterised by enrichment in EGFR signalling. This EGFR signature was also observed to a 
lesser extent in the LNCaP AI model, but not in the VCaP-CR. LNCaP AI tumours were 
characterised by an increased expression of several components of the mitochondrial electron 
transport chain as well as of the unfolded protein response, while the VCaP-CR tumours 
displayed down-regulation of a large cluster of mitosis-associated proteins (Supplementary 
Data 1). This heterogeneity was further exemplified by different patterns of AR expression 
following ADT across the different models (decreased in 22rv1 when compared to CWR22res, 
increased in LNCaP AI compared to LNCaP, and strongly increased in VCaP-CR tumours in 
comparison to VCAP, Figure 1d). Finally, we took advantage of our proteomic approach to 
generate a proteomic signature characteristic of CRPC, irrespective of tumour type or AR 
status. We compared our proteomic datasets to identify proteins that were commonly 
modulated in all three models of CRPC. Interestingly, only 8 proteins were commonly 
regulated across the different models (FC = 2; p-value < 0.05; Figure 1b). Among these 
candidates, Adducin-1 (ADD1) and Schlafen Family Member 5 (SLFN5) were significantly 
more abundant in all CRPC tumours. Unlike ADD1, the role of SLFN5 in cancer remains 
understudied, which prompted us to explore its function in CRPC. 
  
SLFN5 is an AR-regulated gene highly expressed in CRPC 
We first confirmed high SLFN5 levels in CRPC orthografts by performing western blot 
on total tumour lysates (Figure 2a). Immunohistochemistry performed on tumour slides further 
evidenced a strong nuclear staining for SLFN5 in epithelial cells. In agreement with the 
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proteomic data, SLFN5 staining was more intense in 22rv1 and LNCaP AI tumours, when 
compared to their HN counterparts (Figure 2b). Increased SLFN5 expression was also observed 
in vitro following long-term androgen deprivation (Figure 2c), and was low in normal prostate 
epithelial cells (RWPE-1) when compared to PCa cells (Supplementary Figure 2a). AR is the 
main driver of ADT resistance (6) and directly regulates the expression of multiple genes 
involved in a plethora of biological processes that, if aberrantly regulated, are known to cause 
cancer pathogenesis (25). Therefore we tested the ability of AR to modulate SLFN5 expression 
in PCa cells. In LNCaP, short-term androgen deprivation (72 h) was sufficient to increase 
SLFN5 mRNA by almost four-fold, and this effect was partially rescued by the addition of 
dihydrotestosterone (DHT) (Figure 2d). Furthermore, DHT treatment significantly decreased 
SLFN5 expression, at both mRNA and protein levels, in multiple PCa cell lines (Figure 2e-f). 
In general, SLFN5 expression was increased upon androgen withdrawal and showed an inverse 
correlation with AR expression (Figure 2g). To assess the contribution of AR to SLFN5 
regulation, we first silenced AR (full length, AR-FL) using siRNA in both LNCaP and 
CWR22res cells. We also evaluated the ability of AR-V7 to regulate SLFN5 expression by 
performing specific knockdown (KD) of the AR-Vs variants in CWR22Rv1-AR-EK cells, a 
CRISPR-engineered PCa cell line that has lost expression of AR-FL while the expression of 
AR variants was maintained (26). In both cases, AR silencing significantly increased SLFN5 
expression (Figure 2h-i, Supplementary Figure 2b-c). Interestingly, SLFN5 expression was 
inversely correlated to the expression of the canonical AR target gene KLK3 in PCa patients 
(using the PRAD TCGA dataset, Figure 2j). In another dataset of mCRPC patients (27), we 
further observed that high-SLFN5 expressing tumours (EXP > 1.4) displayed significantly low 
levels of AR and AR-V7 (Supplementary Figure 2d). Finally, we confirmed the binding of AR 
on the promoter region of SLFN5 using chromatin immunoprecipitation (ChIP) (Figure 2k), 
thus validating SLFN5 as an AR target in PCa. 
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SLFN5 is associated with poor outcome in PCa patients 
To assess the clinical relevance of SLFN5, we applied immunohistochemistry to assay 
for SLFN5 protein expression in a cohort of radical prostatectomy specimens. Similar to data 
from orthografts, SLFN5 immunoreactivity was primarily observed in the nuclei of epithelial 
cells (Figure 3a). SLFN5 expression was found to be highest in CRPC tumours (n = 45, p < 
0.0001), followed by CRPC tumours with a neuroendocrine phenotype (NEPC, n = 29, p = 
0.0165) in comparison to treatment naïve tumours (n = 151) (Figure 3b). Interestingly, 
compared to untreated tumour, SLFN5 expression was not altered following neo-adjuvant 
hormonal therapy (NHT-treated, median treatment time of 6 months, n = 162). High SLFN5 
expression in patients significantly correlated with shorter relapse free survival (evaluated as 
time to biochemical relapse, p = 0.004, Figure 3c). Furthermore, SLFN5 expression was 
significantly elevated in high Gleason score tumours (>7 versus ≤7, p = 0.013) (Figure 3d) and 
was significantly associated with increased risk of metastasis (p-value = 0.0003) (Figure 3e). 
Taken together, these results suggest that SLFN5 expression is associated with 
progressive disease in PCa. 
 
SLFN5 loss impairs in vivo growth of CRPC tumours 
 To evaluate the functional importance of SLFN5 in CRPC, we used CRISPR-CAS9 
technology to generate SLFN5 knockout (SLFN5 KO) clones in 22rv1 and LNCaP AI cells 
and assessed the proliferative and migratory abilities of CRPC cells in vitro (Figure 4a). SLFN5 
KO significantly reduced the proliferation of LNCaP AI, but not 22rv1 cells (Figure 4b). 
Importantly, SLFN5 loss consistently impaired cell migration in both cell types, and this effect 
was further observed using transient SLFN5 KD (Figure 4c-e).  
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Because SLFN5 was originally discovered in an in vivo proteomic screen, we 
speculated whether SLFN5 could affect the growth of CRPC tumours in vivo. To test this 
hypothesis, 22rv1 control and SLFN5 KO (CTL and KO respectively) cells were orthotopically 
injected into castrated mice and tumour volume was monitored weekly using ultrasonography. 
While SLFN5-deficient cells remained able to form solid tumours in CRPC condition (Figure 
4f-g), tumour growth was strongly reduced in absence of SLFN5 (Figure 4h). In addition, 
partial or total tumour regression was also observed in around 25% of SLFN5 KO tumours 
(Figure 4i). Taken together, these results suggest that SLFN5 is important for tumour 
adaptation to CRPC condition, rather than for tumour initiation, and inhibiting SLFN5 may 
present as a potential target to regress some tumours. 
  
SLFN5 depletion remodels the transcriptome of CRPC cells 
 SLFN5 has been described as a transcriptional modulator in glioblastoma (19). In 
agreement with a potential role in regulating transcriptional activity, SLFN5 was expressed in 
the nucleus of CRPC cells (Figure 5a). To understand the molecular functions of SLFN5, we 
compared the transcriptome of SLFN5 KO and CTL 22rv1 cells (Supplementary Data 2). Loss 
of SLFN5 resulted in significant alteration of 428 genes (FC = 2; p-value < 0.05), with 331 up-
regulated and 97 down-regulated genes in the same direction in both KO clones when 
compared to CTL cells (Figure 5b). Enrichment Pathway Analysis emphasised that many 
transcripts altered in SLFN5 KO cells encoded for plasma membrane proteins. Cell adhesion 
was one of the top up-regulated pathways (FC > 2), while cell locomotion/migration, 
extracellular matrix organisation and ion transport were among the pathways that were 
significantly reduced in KO cells (FC < -2) (Figure 5c and Supplementary Data 3). We 
performed a similar RNAseq analysis on SLFN5-proficient and -depleted 22rv1 orthografts. 
Even with higher variability among in vivo tumour samples, we observed 88 genes that were 
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significantly modulated in SLFN5-deficient tumours (FC = 2, p-value < 0.05), with the 
majority (n = 68) of these genes being down-regulated in KO tumours (Figure 5b, 
Supplementary Data 2). Importantly, 22 genes were strongly down-regulated (FC < -3) in 
absence of SLFN5 in both the in vitro and in vivo analyses. This allowed us to define a signature 
of SLFN5-target genes in CRPC (Supplementary Table 1). Finally, RNAseq expression data 
for the top down-regulated candidates were validated by qPCR (Figure 5d).  
To assess whether the transcriptional changes occurring in the absence of SLFN5 would 
reflect at the protein level, we further performed a proteomic comparison of the SLFN5 KO 
and CTL orthografts. The analysis highlighted 25 proteins that were significantly modulated 
(FC = 2, p-value < 0.05) in the absence of SLFN5 (Figure 5e). Among these candidates, 5 
proteins (NDNF, STRBP, UBAP2, SLC7A5 and SLC3A2) belonged to the SLFN5-gene 
signature defined in Supplementary Table 1. Moreover NDNF, STRBP, UBAP2 and SLC7A5 
transcript levels strongly correlated with SLFN5 expression in PCa patients (Figure 5f, PRAD 
TCGA dataset), thus supporting a potential transcriptional regulation by SLFN5.  
Of note, SLC7A5 and SLC3A2 are the functional components of the AA transporter 
LAT1 which has recently gained interest as a molecular target for cancer therapies (28). We 
therefore sought to explore the link between SLFN5 and LAT1 in PCa. 
  
SLFN5 controls LAT1 expression in CRPC 
 Down-regulation of the LAT1 (SLC7A5/SLC3A2) complex was confirmed in 22rv1-
derived SLFN5 KO cells and orthografts (Figure 6a-b). Importantly, SLC7A5 expression was 
also decreased in LNCaP AI SLFN5 KO cells (Figure 6c) and in SLFN5-depleted PC3M cells, 
a metastatic PCa cell line displaying high levels of SLFN5 expression (Supplementary Figure 
3a). Conversely, LAT1 expression was increased following SLFN5 overexpression in LNCaP 
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cells (Figure 6d). Overall, SLC7A5 protein level was high in CRPC cell lines when compared 
to HN cells, and positively correlated with SLFN5 expression (Figure 6e).  
We next investigated the mechanism by which SLFN5 regulates LAT1 in CRPC. In a 
recent study, ChIPseq analysis following SLFN5 immunoprecipitation revealed the presence 
of SLFN5-specific binding motifs in the genome of breast cancer cells (18). Interestingly, both 
SLC7A5 and SLC3A2, as well as NDNF and STRBP, displayed enrichment of SLFN5-binding 
motifs in their promoters (Supplementary data 4). However, transient silencing of SLFN5 by 
siRNA only moderately reduced SLC7A5 expression (Figure 6f). SLC7A5 and SLC3A2 have 
also been reported as ATF4 target genes in cancer (13). In addition, negative enrichment of 
several ATF4-related genesets was observed in the transcriptomic analysis of the SLFN5 KO 
tumours (Figure 6g and Supplementary Figure 3b), and majority of the 22 SLFN5-regulated 
genes (Figure 5b, Supplementary Table 1) were predicted to harbour strong binding sites for 
ATF4 (Supplementary data 5). We therefore hypothesized that SLFN5 could act as a 
transcriptional modulator of ATF4 in PCa. Co-immunoprecipitation on nuclear extracts, as 
wells as proximity ligation assay, both supported the presence of a direct interaction between 
SLFN5 and ATF4 (Figure 6h-i). Moreover, enrichment of the SLFN5-specific motif was 
observed in the ATF4 promoter (Supplementary data 4) and SLFN5 depletion indeed reduced 
ATF4 mRNA expression (Figure 6f). Silencing of ATF4 in 22rv1 cells also led to a strong 
decrease in SLC7A5 mRNA expression, and this effect was amplified when SLFN5 and ATF4 
were both silenced concomitantly (Figure 6f). Finally, co-silencing of SLFN5 and ATF4 also 
reduced the expression of other genes within the SLFN5 signature, such as KCNH5, NCMAP 
and NCCRP1 (Supplementary Figure 3c). Taken together, these results suggest a role for 
SLFN5 in the ATF4-mediated regulation of LAT1 in CRPC. 
 
SLFN5 drives LAT1-mediated activation of mTOR in CRPC 
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LAT1 is a large neutral AA transporter that controls the cellular uptake of branched 
chain and aromatic AAs in exchange of glutamine (10). Hence, LAT1 expression is crucial for 
the regulation of cancer cell metabolism. To evaluate the impact of SLFN5-LAT1 depletion on 
the metabolism of CRPC cells, we compared the metabolic profiles of 22rv1 CTL and SLFN5 
KO cells using quantitative LC-MS metabolomics. Consistent with the role of LAT1 in AA 
homeostasis, we observed that the levels of many AAs (Lys, Arg, Orn, Met, Leu, Ile, Tyr) were 
decreased in the SLFN5 KO cells (Figure 7a). By contrast, SLFN5-deficient cells also showed 
elevated levels of glutathione, in both reduced and oxidised forms (Figure 7a). 
Changes in amino acid homeostasis are known to regulate the mTOR signalling 
pathway (29). Consistent with the observed changes in AA levels, SLFN5-deficient cells 
exhibited impaired mTOR activity, as evidenced by decreased phosphorylation levels of S6K 
and S6 proteins, which are two downstream targets of mTORC1 (Figure 7b). To test whether 
mTOR activation was dependent on LAT1, we stably re-expressed a myc-tagged version of 
SLC7A5 in SLFN5-deficient cells (Figure 7c). Reintroducing SLC7A5 in SLFN5 KO cells 
was sufficient to restore the phosphorylation levels of S6K and S6, therefore indicating that 
impaired mTOR signalling in SLFN5-deficient cells was due, at least in part, to the decrease 
in LAT1 expression. Importantly, impaired mTOR signalling was also observed in vivo in 
SLFN5 KO orthografts (Figure 7d). Finally, using the PRAD TCGA dataset we identified 
proteins that were significantly modulated in high vs. low SLFN5 tumours (Figure 7e). 
Strikingly, several down-stream effectors of the mTOR signalling pathway (p-AKT Ser473, p-
S6 Ser235-236 and Ser240-244, p-4EBP1 Thr37 and p-mTOR Ser2248) were positively 
enriched in high SLFN5 tumours (Figure 7f). Taken together, these results suggest SLFN5 as 
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Overcoming resistance to AR targeted therapies remains the ultimate goal for the 
treatment of advanced PCa. CRPC develops in the majority of patients treated with ADT and 
is often associated with metastasis. The molecular heterogeneity of the CRPC disease reflects 
the numerous ways that tumours can evolve to escape current therapies. Indeed, point mutations 
(30,31), genomic deletion (32) or amplification (33) of the AR gene, reprogramming of AR 
signalling (34) as well as compensations from other signalling pathways (32,35) can all account 
for resistance to ADT (36). In this study, we characterised three different in vivo models that 
were generated to specifically study CRPC and ADT resistance. These models consist of the 
orthotopic injection of three pairs of isogenic, AR-responsive, human cancer cell lines into the 
prostate of immuno-deficient mice, before undergoing orchidectomy to achieve ADT. In depth 
proteomic characterisation of these three models highlighted pathways and molecular markers 
that are commonly involved in CRPC. Despite molecular differences between the models, that 
is reminiscent of the molecular heterogeneity observed in clinical CRPC samples (36), our 
analysis indicated that resistance to ADT was accompanied with a major rewiring of tumour 
metabolism, especially lipid and AA metabolism. In addition to steroid biogenesis, which plays 
an important role in CRPC development (37), branched chain amino acid (BCAA) and fatty 
acid (FA) degradation were strongly dysregulated upon resistance to ADT. BCAA catabolism 
serves to replenish the tricarboxylic acid cycle and is dysregulated in PCa (38), while targeting 
FA metabolism has been proposed as a therapeutic option in the context of CRPC and 
enzalutamide resistance (39,40). Ferroptosis, another lipid-related process that has recently 
been suggested as an important resistance mechanism against AR targeted therapies (6), was 
also enriched in our CRPC models. Likewise, peroxisome proliferator-activated receptor 
(PPAR) signalling was commonly enriched in all three models of CRPC orthografts. While AR 
itself remains the most influential regulator of PCa metabolism (5), the contribution of PPAR 
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signalling pathways to the regulation of PCa lipid metabolism has recently gained interest. For 
example, PPARγ has been identified as a critical regulator of PCa invasion and metastasis (41), 
while PPARα is an established AR target gene that is overexpressed in advanced PCa (42).  
As well as uncovering the molecular pathways that are associated with CRPC, our 
analysis allowed us to define a repertoire of several candidates whose expressions were 
robustly associated with CRPC. Among these proteins, we focused our attention on Schlafen 
Family Member 5, a potential transcription co-regulator whose expression had not yet been 
reported in PCa. SLFN5 expression was increased in CRPC patients and was associated with 
poor clinical outcome. This increase in expression can be explained by the AR-dependent 
regulation of SLFN5 in prostate cells, an observation that was further supported by the presence 
of AR-binding sites in the promoter region of SLFN5 (43,44) and by the negative correlation 
observed between SLFN5 levels and AR, ARv7 and KLK3 expressions in prostate tumours. 
Furthermore, in vitro SLFN5 expression was reciprocally modulated following manipulation 
of AR function (with androgen supplements, androgen withdrawal, silencing of AR 
expression) in multiple PCa cell lines. However, whether the AR-dependent regulation of 
SLFN5 expression in CRPC tumours is directly mediated by AR or requires additional co-
factors remains to be fully tested. In line with a pro-malignant role of SLFN5 in PCa, CRISPR-
mediated KO of SLFN5 in CRPC cells reduced cell migration and further impaired CRPC 
tumour growth in castrated mice. The role of SLFN5 in cancer remains controversial. In 
contrast to our data, early studies in melanoma (15), breast (16) and renal cell carcinoma (17) 
suggested that high SLFN5 expression was correlated with favourable patient outcomes. 
Moreover, in these cell types, SLFN5 silencing resulted in enhanced cell migration and 
invasion, thus suggesting a tumour suppressive role for SLFN5. Conversely, pro-tumoural 
properties of SLFN5 have been described in glioblastoma (GBM), along with a transcriptomic-
informed signature of SLFN5 genes in U87 glioblastoma cells (19). Surprisingly, there was 
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little overlap between the SLFN5 gene signature that we identified in CRPC cells and that 
reported for U87 cells, raising the possibility that SLFN5-mediated transcriptional activities 
might be cell type and/or context dependent. 
By combining transcriptomics and proteomics, we identified SLC7A5 and SLC3A2, 
the two components of the LAT1 amino acid transporter, as targets of SLFN5 in CRPC. LAT1 
is a member of the system L transporter family and mediates the intracellular uptake of BCAA 
and aromatic AA in exchange for glutamine (11). In PCa, LAT1 expression is associated with 
an increased risk of metastasis (13). LAT1 is also up-regulated following androgen deprivation 
(12,13) and is an independent predictor of castration resistance (12). Moreover targeting LAT-
dependent AA transport has shown promising results in preclinical models (28). In CRPC cells, 
SLFN5 KO led to a strong downregulation of the LAT1 transporter, although the molecular 
mechanisms underlying this observation remain to be fully uncovered.  
Based on our observation that transient SLFN5 silencing only moderately reduced 
SLC7A5 expression, we hypothesised that SLFN5 co-regulated SLC7A5 expression along 
with another transcription factor. An interesting candidate is the stress-induced factor ATF4, 
which has been implicated in CRPC (45). Indeed, SLC7A5 is an established target of ATF4 in 
PCa (13), and we have shown that SLFN5 and ATF4 were able to physically interact with each 
other. Moreover, the majority of the SLFN5-regulated genes (Supplementary Table 1) 
displayed strong ATF4-binding sites, and both ATF4 and SLC7A5 also presented SLFN5-
enriched motifs in their promoter region. Finally, co-silencing of SLFN5 and ATF4 
dramatically reduced the expression of the LAT1 transporter. Additional research is required 
to further define the molecular mechanisms connecting SLFN5 and ATF4 in the context of 
CRPC. 
Consistent with a role for LAT1 in maintaining AA homeostasis, we observed that 
SLFN5 KO cells displayed low intracellular levels of essential AA, which are potent activators 
Research. 
on May 25, 2021. © 2021 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 13, 2021; DOI: 10.1158/0008-5472.CAN-20-3694 
26 
 
of mTORC1 signalling. Leucine for example is important to maintain mTORC1 localisation at 
the lysosomal surface, subsequently allowing activation of the downstream signalling pathway 
(9). Therefore a role for LAT1 in stimulating mTORC1 signalling has been reported in the 
pathology of multiple diseases (11). mTOR is also frequently dysregulated in advanced prostate 
cancer (7) and targeting this pathway has shown promising results in preclinical models (46). 
However, mTOR inhibitors have shown limited efficacy in the clinic (8). One reason could be 
that only a subpopulation of PCa patients might benefit from such mTOR-targeted therapies. 
Interestingly, using publicly available data, we showed that high SLFN5 levels in patients 
correlate with increased phosphorylation levels of multiple down-stream effectors of the 
mTOR signalling pathway (p-mTOR, p-S6 and p-4EBP1). Therefore, SLFN5 expression, as 
well as the identification of a CRPC specific SLFN5-gene signature, could help in stratifying 
patients that would benefit from mTOR inhibition and may present as a potential therapeutic 
candidate to resensitize patients to treatment. 
 In conclusion, this study provides an in-depth characterisation of three PCa orthografts 
as preclinical models of CRPC aimed to recapitulate molecular features of ADT resistance in 
PCa. Our results confirm the suitability of these orthograft models to account for the high 
degree of heterogeneity observed in CRPC patients, and further highlight the transcriptional 
modulator SLFN5 as a clinically relevant target for CRPC. Mechanistically, SLFN5 controls 
the expression of the LAT1 transporter in CRPC cells, potentially acting through an ATF4-
dependent mechanism. As a result SLFN5 deletion impairs CRPC tumour growth in vivo, alters 
CRPC cell metabolism and disrupts mTORC1 signalling in a LAT1-dependent manner. Taken 
together, our results support the idea of targeting metabolism for the treatment of PCa, and 
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Figure 1: Proteomic characterisation of in vivo CRPC orthografts. A, Schematic 
representation of the three CRPC orthograft models used in this study. B, Venn diagrams 
highlighting proteins commonly modulated (p-value < 0.05, FC = 2) in CRPC orthografts in 
comparison to their respective HN counterparts. Up-regulated proteins are on top; Down-
regulated proteins are into brackets. C, Top 20 enriched pathways (KEGG pathways) 
significantly modulated in the proteomic analysis of CRPC orthografts. Pathway enrichment 
analysis was performed using the STRING database (http://string-db.org). D, Western blot 
analysis of AR expression in HN and matched CRPC tumour orthografts. HSC70 was used as 
a sample loading control.  
Figure 2: SLFN5 is an AR-regulated gene. A, Western blot analysis of SLFN5 expression in 
HN and matched CRPC tumour orthografts. B, Immunohistochemical staining (top) of SLFN5 
expression in HN (CWR22res and LNCaP) and matched CRPC (22rv1 and LNCaP AI) 
orthografts; and representative pictures of hematoxylin/eosin staining (bottom) of the 
corresponding orthografts. Scale bar represents 50 µm. C, Western blot analysis of SLFN5 
expression in HN and matched CRPC cell lines. D, RT-qPCR analysis of SLFN5 expression in 
LNCaP cells treated with DHT for 48 hours in androgen-depleted (CSS) conditions. E, RT-
qPCR analysis of SLFN5 expression in AR+ PCa cells following short term DHT treatment (10 
nM). F, Western blot analysis of SLFN5 expression in CRPC cell lines treated with DHT for 
72 hours. G, Western blot analysis of SLFN5 and AR expression in LNCaP and LNCaP AI 
cells cultured in presence (FBS medium) or absence (CSS medium) of androgens for 72 hours. 
H, RT-qPCR analysis of SLFN5 expression in LNCaP and CWR22res cells silenced for AR 
expression. I, RT-qPCR analysis of SLFN5 expression in CWR22Rv1-AR-EK cells silenced 
for AR-Vs expression. J, Correlation of SLFN5 and KLK3 mRNA levels in the PRAD TCGA 
dataset (cbioportal). K, RT-qPCR analysis of the SLFN5 and KLK3 promoters after anti-AR 
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chromatin immunoprecipitation performed in 22rv1 cells. Panels A, C, F, G: HSC70 is used 
as a sample loading control. Panels D, E, H: CASC3 was used as a normalising control. Panel 
I: RPL13A was used as a normalising control. Panels D, E, H, I, K: Data are presented as mean 
values +/- SD. Panel D: *p-value using a 1-way ANOVA with a Tukey’s multiple comparisons 
test. Panel E: *p-value using a 1-way ANOVA with a Dunnett’s multiple comparisons test. 
Panels H, I, K: *p-value using a two-sided Student’s t-test. 
Figure 3: SLFN5 expression is high in CRPC tumours and correlates with poor patient 
outcome. A, Immunohistochemical staining of SLFN5 expression in treatment naïve, NHT-
treated, CRPC and NEPC tumours. Scale bar represents 100 µm. B, Quantification of SLFN5 
expression in PCa tissue samples. C, Kaplan-Meier relapse-free survival analysis of prostate 
cancer patients stratified according to median SLFN5 expression. Time to PSA recurrence was 
used as biochemical parameter. D, E, Quantification of SLFN5 expression in PCa tissue 
samples according to Gleason score and metastatic status. Centre line corresponds to median 
of data, top and bottom of box correspond to 95th and 5th percentile, respectively. Whiskers 
extend to adjacent values (minimum and maximum data points not considered outliers). Panel 
B: statistical analysis was performed using a 1-way ANOVA with a Dunnett’s multiple 
comparisons test. Panel C: statistical analysis was performed using a log rank test. Panels D, 
E: statistical analysis was performed using a two-tailed Mann-Whitney U test. 
Figure 4: SLFN5 KO affects CRPC in vitro cell migration and in vivo tumour growth. A, 
Western blot analysis of SLFN5 expression in SLFN5 KO cells. HSC70 is used as a sample 
loading control. B, Cell proliferation of SLFN5 KO (knockout) and untargeted control (CTL) 
cells after 24, 48 and 72 hours. Cell count is normalised to initial number of cells at the start of 
the experiment. C, Cell migration of LNCaP AI SLFN5 KO (knockout) and untargeted control 
(CTL) cells after 48 hours. D, Cell migration of 22rv1 SLFN5 KO (knockout) and untargeted 
control (CTL) cells after 48 hours. E, Cell migration of 22rv1 siSLFN5 (knockdown) and 
Research. 
on May 25, 2021. © 2021 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 13, 2021; DOI: 10.1158/0008-5472.CAN-20-3694 
33 
 
untargeted siCTL (control) cells after 48 hours. F, Representative pictures of 22rv1-derived 
SLFN5 KO (knockout) and untargeted control (CTL) tumour orthografts. G, Representative 
pictures of hematoxylin/eosin staining of the corresponding tumour orthografts. Scale bar 
represents 100 µm. H, Representative pictures of 22rv1 CTL or SLFN5 KO tumour orthografts 
monitored by ultrasound imaging (top). Quantification of tumour volume along time using 
ultrasonography (bottom). I, same as H but individual tumours are plotted on separate graphs. 
Panels B, C, D, E, H: Data are presented as mean values +/- SD. Panels B, C, D: *p-value < 
0.05 using a 1-way ANOVA with a Dunnett’s multiple comparisons test. Panel E: *p-value 
using a two-sided Student’s t-test. Panel H: *p-value < 0.05 using a 2-way ANOVA with a 
Dunnett’s multiple comparisons test.  
Figure 5: SLFN5 KO remodels the transcriptome of CRPC cells. A, Immunofluorescence 
showing nuclear SLFN5 expression in LNCaP and LNCaP AI cells. Scale bar represents 10 
µm. B, Venn diagrams highlighting genes commonly modulated (p-value < 0.05, FC = 2) in 
SLFN5 KO cells (top) and tumours (bottom) when compared to their respective controls. Up-
regulated genes are on top; Down-regulated genes are into brackets. C, Schematic 
representation of the down-regulated genes (p-value < 0.05, FC = 2) in SLFN5 KO cells when 
compared to CTL cells. Pathway enrichment analysis was performed using the STRING 
database (http://string-db.org). D, RT-qPCR analysis of SLFN5 and top downregulated genes 
from B in SLFN5 KO and CTL cells. E, Volcano plots showing the proteins significantly 
modulated (p-value < 0.05, FC = 2) in the proteomic analysis of SLFN5 KO tumours. F, 
Pearson’s correlation analysis of NDNF, STRBP, UBAP2 and SLC7A5 with SLFN5 using the 
PRAD TCGA dataset. Results were obtained using the GEPIA website http://gepia.cancer-
pku.cn/. Panel D: Data are presented as mean values +/- SD. Panel D: *p-value < 0.05 using a 
1-way ANOVA with a Dunnett’s multiple comparisons test. Panel F: statistical analysis was 
performed using a logrank test. 
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Figure 6: SLFN5 regulates LAT1 expression in CRPC. A, Western blot analysis of SLFN5, 
SLC7A5 and SLC3A2 expression in 22rv1 SLFN5 KO and CTL cells. B, Western blot analysis 
of SLFN5, SLC7A5 and SLC3A2 expression in 22rv1-derived SLFN5 KO and CTL tumour 
orthografts. C, Western blot analysis of SLFN5 and SLC7A5 expression in LNCaP AI SLFN5 
KO and CTL cells. D, Western blot analysis of SLFN5 and SLC7A5 expression in LNCaP 
cells overexpressing SLFN5. E, Western blot analysis of SLFN5 and SLC7A5 expression in 
HN and matched CRPC cell lines. F, RT-qPCR analysis of SLFN5, SLC7A5 and ATF4 
expression in 22rv1 cells silenced for SLFN5, ATF4 or both. G, Gene set enrichment plots 
analysed from SLFN5-depleted tumours transcriptomics using ATF4-related gene set obtained 
from Han et al, 2013. H, Western blot analysis of SLFN5 and ATF4 expression following anti-
SLFN5 immunoprecipitation in nuclear extracts of 22rv1 cells. I, Proximity ligation assay of 
SLFN5 and ATF4 performed on 22rv1 cells. Red dots represent co-localisation. Scale bar 
represents 11 µm. Panels A, B, C, D, E: HSC70 is used as a sample loading control. Panel F: 
Data are presented as mean values +/- SD. Panel F: *p-value < 0.05 using a 1-way ANOVA 
with a Tukey’s multiple comparisons test. 
Figure 7: SLFN5 expression promotes LAT1-dependent activation of mTORC1 
signalling in CRPC. A, Steady-state levels of significantly regulated metabolites in SLFN5 
KO cells when compared to CTL cells (FC > 1.2). Selected metabolites were significantly 
altered in at least one of the two KO cells (p < 0.05 using two-sided Student’s t-test). B, Western 
blot analysis of SLFN5, SLC7A5, SLC3A2, p-p70S6K, p70S6K and p-S6 expression in 22rv1 
SLFN5 KO and CTL cells. C, same analysis as B performed on 22rv1 SLFN5 KO and CTL 
cells overexpressing two different SLC7A5 constructs. D, Western blot analysis of p-S6 and 
p-4EBP1 expression in 22rv1-derived SLFN5 KO and CTL tumour orthografts. E, Volcano 
plot of the modulated proteins between high and low SLFN5 tumours using the PRAD TCGA 
dataset. Red and blue dots represent the proteins that are significantly up-regulated and down-
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regulated (FC = 1.2, p < 0.05) in high SLFN5 tumours respectively. F, Differential expression 
of p-S6 (Ser235-236 and 240-244) and p-4EBP1 (Thr37) in high and low SLFN5 tumours, 
according to the data generated in E. Centre line corresponds to median of data, top and bottom 
of box correspond to 90th and 10th percentile, respectively. Whiskers extend to adjacent values 
(minimum and maximum data points not considered outliers). Panels B, C, D: HSC70 is used 
as a sample loading control. Panel A: Data are presented as mean values +/- SD. Panel F: 
statistical analysis was performed using a two-tailed Mann-Whitney U test. 
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